Trevi Therapeutics (TRVI) officer receives 35,000-share stock option grant

Rhea-AI Filing Summary

Trevi Therapeutics, Inc. reported that company officer Christopher Galletta received a grant of stock options covering 35,000 shares of common stock. The award was made on February 19, 2026 as a compensation-related acquisition, not an open-market purchase.

The 35,000 underlying shares are scheduled to vest in equal monthly installments through February 19, 2030, conditioned on Galletta’s continued service with the company. This filing simply records the new equity award and Galletta’s resulting direct ownership of these options.

Insider Trade Summary

1 transaction reported

Mixed 1 txn

Insider Galletta Christopher

Role See Remarks

Type	Security	Shares	Price	Value
Grant/Award	Stock Option (right to buy)	35,000	$0.00	--

Holdings After Transaction: Stock Option (right to buy) — 35,000 shares (Direct)

Footnotes (1)

1. [object Object]

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Galletta Christopher

(Last) (First) (Middle)

C/O TREVI THERAPEUTICS, INC.

195 CHURCH STREET, 16TH FLOOR

(Street)

NEW HAVEN CT 06510

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Trevi Therapeutics, Inc. [ TRVI ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	See Remarks

3. Date of Earliest Transaction (Month/Day/Year)
02/19/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (right to buy)	$10.56	02/19/2026		A		35,000		(1)	02/18/2036	Common Stock	35,000	$0	35,000	D

Explanation of Responses:

1. This option was granted on February 19, 2026. The 35,000 shares of common stock underlying the option are scheduled to vest in equal monthly installments through February 19, 2030, subject to the reporting person's continued service with the issuer.

Remarks:

Controller and Principal Accounting Officer

	/s/ Christopher Galletta	02/20/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What does the Trevi Therapeutics (TRVI) Form 4 disclose about Christopher Galletta?

The Form 4 shows that Trevi Therapeutics officer Christopher Galletta received a grant of stock options for 35,000 shares of common stock. This is an equity award reflecting compensation, not an open-market stock purchase or sale.

How many Trevi Therapeutics (TRVI) shares are covered by Galletta’s new option grant?

The option grant covers 35,000 shares of Trevi Therapeutics common stock. These shares are underlying a single stock option award reported as a derivative security, increasing Galletta’s potential equity exposure if the options eventually become exercisable and are exercised.

What is the vesting schedule for Christopher Galletta’s TRVI stock options?

The 35,000 shares underlying the option are scheduled to vest in equal monthly installments through February 19, 2030. Vesting is conditioned on Galletta’s continued service with Trevi Therapeutics, aligning the award with ongoing employment over several years.

Is the TRVI Form 4 for Christopher Galletta a stock purchase or a compensation grant?

The filing reflects a grant of stock options, classified as a “grant, award, or other acquisition,” not an open-market stock purchase. It records a compensation-related derivative award rather than a discretionary buy or sell of Trevi Therapeutics common shares.

How did this TRVI option grant change Christopher Galletta’s reported holdings?

After the transaction, Galletta is reported as directly holding 35,000 stock options linked to Trevi Therapeutics common shares. These options vest monthly through February 19, 2030, so the economic benefit depends on continued service and any future exercise decisions.